Screener
Nuvation Bio NUVB Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Nuvation Bio in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Nuvation Bio’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 6:55 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336646
FAQ
- What is Nuvation Bio's cash & equivalents?
- Nuvation Bio (NUVB) reported cash & equivalents of $258.6M in Q2 2026.
- How has Nuvation Bio's cash & equivalents changed year-over-year?
- Nuvation Bio's cash & equivalents increased by 4.3% year-over-year, from $247.97M to $258.6M.
- What is the long-term trend for Nuvation Bio's cash & equivalents?
- Over 5 years (2020 to 2025), Nuvation Bio's cash & equivalents has grown at a 40.7% compound annual growth rate (CAGR), from $29.76M to $164.09M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Nuvation Bio's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude